Ocuphire Pharma

Ocuphire Pharma, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Farmington Hills, MI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Opus Genetics, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Farmington Hills, MI.

Ocuphire Pharma, Inc. (NASDAQ:OCUP ) Corporate Update Call December 5, 2023 10:00 AM ET Company Participants Dr. George Magrath - Chief Executive Officer Michael Wood - LifeSci Advisors Charlie Hoffmann - SVP of Corporate Development Ronil Patel - Chief Business Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald John Newman - Canaccord Genuity Operator Greetings. Welcome to Ocuphire Pharma Incorporated Corporate Update Call with CEO Dr. George Magrath.

Ocuphire Pharma, Inc. (OCUP) Ocuphire Pharma Corporate Update Call (Transcript)

Ocuphire Pharma, Inc. (OCUP) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Bears are Losing Control Over Ocuphire Pharma, Inc. (OCUP), Here's Why It's a 'Buy' Now

Investor Call with CEO, George Magrath, M.D., M.B.A., M.S. on December 5, 2023 Investor Call with CEO, George Magrath, M.D., M.B.A., M.S. on December 5, 2023

Ocuphire Pharma Announces Presentation at Ophthalmology Innovation Summit (OIS) XIII

D-MARKET Electronic Services

Power Solutions

After a rocky couple of years, there finally seems to be some light at the end of the tunnel for growth stocks. Interest rates have stabilized, and the economy is again showing signs of strength.

Buy Alert: Analysts Say These 3 Growth Stocks Could Double in 2024

FARMINGTON HILLS, Mich., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced that the independent members of its Board of Directors approved an equity award under Ocuphire's 2021 Inducement Plan, as a material inducement to Joseph K. Schachle, the Company's newly appointed Chief Operating Officer, in connection with his employment with the Company effective on November 27, 2023. The equity award was approved in accordance with Nasdaq Listing Rule 5635(c)(4), which also requires a public announcement of equity awards that are not made under a stockholder approved equity plan.

Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Mr. Schachle Brings Over 30 Years of Experience in Biotech and Pharma with Expertise Across Multiple Functional Areas Including Corporate and Commercial Operations Mr. Schachle Brings Over 30 Years of Experience in Biotech and Pharma with Expertise Across Multiple Functional Areas Including Corporate and Commercial Operations

Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer

Successful End-of-Phase 2 Meeting with FDA for Oral APX3330; Agreement on Phase 3 Registration Endpoint RYZUMVI ™ Approved by FDA; Ocuphire Received $10 million Regulatory Milestone Payment VEGA-2 Phase 3 Presbyopia Trial Met Primary Endpoint; Viatris Expected to Continue Phase 3 Development in 1H 2024 George Magrath, M.D., M.B.A., M.S.

Ocuphire Pharma Announces Financial Results for Third Quarter 2023 and Provides Corporate Update

Agreement on Phase 3 Primary Endpoint of 3-step Worsening on Binocular Diabetic Retinopathy Severity Scale (DRSS) Score

Ocuphire Pharma Announces Successful End-of-Phase 2 Meeting with FDA for Oral APX3330 in Diabetic Retinopathy

Dr. Magrath Brings Proven Executive Leadership, Medical and Clinical Expertise in Ophthalmic Drug Development Dr. Magrath Brings Proven Executive Leadership, Medical and Clinical Expertise in Ophthalmic Drug Development

Ocuphire Pharma Announces Appointment of George Magrath, M.D., M.B.A., M.S.

FARMINGTON HILLS, Mich., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced presentations featuring APX3330 and phentolamine ophthalmic solution at the American Academy of Ophthalmology Annual Meeting (AAO 2023) to take place in San Francisco, California on November 3-6, 2023. In addition, Jay Pepose, M.D. Ph.D., Chief Medical Advisor at Ocuphire, will provide a corporate overview at the Eyecelerator AAO 2023 Retina Showcase in San Francisco, California on November 2, 2023.

Ocuphire Pharma to Present at AAO 2023 and Eyecelerator Retina Showcase

Presentations Will Feature Data From ZETA-1 Phase 2 Trial of APX3330 in Diabetic Retinopathy Presentations Will Feature Data From ZETA-1 Phase 2 Trial of APX3330 in Diabetic Retinopathy

Ocuphire Pharma to Present at Euretina and Retina Society Conferences in October

Viatris

Viatris Inc. VTRS, and Ocuphire Pharma Inc. OCUP, +3.08% said Wednesday that the U.S. Food and Drug Administration has approved Ryzumvi to treat the side effects of pharmacologically-induced mydriasis, or dilation of pupils. About 100 million eye dilations are conducted in the U.S. each year to examine the retina and for other routine check-ups, the companies said in a release, but the dilation can last up to 24 hours and side effects include light sensitivity and blurred vision.

Viatris and Ocuphire Pharma get FDA green light for eye treatment

RYZUMVI Expected to be Commercially Available in the U.S. in the First Half of 2024 RYZUMVI Expected to be Commercially Available in the U.S. in the First Half of 2024

Ocuphire Pharma and Viatris Announce FDA Approval of RYZUMVI™ (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (e.g., Phenylephrine) or Parasympatholytic (e.g.

RYZUMVI Expected to be Commercially Available in the U.S. in the First Half of 2024   PITTSBURGH, and FARMINGTON HILLS, Mich. , Sept. 27, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, and Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced that the U.S. Food and Drug Administration (FDA) has approved RYZUMVI™  (phentolamine ophthalmic solution) 0.75% for the treatment of pharmacologically-induced mydriasis produced by adrenergic agonists (e.g.

Viatris and Ocuphire Pharma Announce FDA Approval of RYZUMVl™ (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (e.g., Phenylephrine) or Parasympatholytic (e.g.

FARMINGTON HILLS, Mich., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced that company management will be participating in one-on-one meetings at the H.C. Wainwright 25th Annual Global Investment Conference being held in New York City on September 11-13, 2023. Additionally, Ronil Patel, MS, Ocuphire's SVP of Operations & Business Development, will be participating in panel presentations at both the Cantor Annual Global Healthcare Conference being held in New York City on September 26-28, 2023 and the Inaugural Jones Trading 2023 Healthcare Summit being held in Miami Beach on October 9-11, 2023.

Ocuphire Pharma to Participate in Three Upcoming Investment Bank Conferences

ESCRS presentations will feature clinical data on APX3330 in diabetic retinopathy; Nyxol® data in presbyopia, dim light vision disturbance and reversal of pharmacologically induced mydriasis ESCRS presentations will feature clinical data on APX3330 in diabetic retinopathy; Nyxol® data in presbyopia, dim light vision disturbance and reversal of pharmacologically induced mydriasis

Ocuphire Pharma to Present at ESCRS 2023 and MODLive! Conferences in September

ZETA-1 abstract rated as one of top three scoring abstracts out of nearly 600 submissions at WIO and received an award distinction ZETA-1 abstract rated as one of top three scoring abstracts out of nearly 600 submissions at WIO and received an award distinction

Abstract on ZETA-1 Study of APX3330 Receives Award at Women in Ophthalmology (WIO) Summer Symposium

End-of-Phase 2 Meeting with FDA Scheduled for Q4 2023 for Oral APX3330 in Diabetic Retinopathy (DR) Cash Balance of $40 Million Expected to Fund Operations into 2025 Nyxol RM PDUFA date September 28, 2023; Approval would trigger $10 million milestone payment to Ocuphire Common Share Purchase Agreement with Lincoln Park Capital Fund, LLC providing up to $50 million in committed financing over 30 months FARMINGTON HILLS, Mich., Aug. 11, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced financial results for the second quarter ended June 30, 2023, and provided a corporate update.

Ocuphire Pharma Announces Financial Results for Second Quarter 2023 and Provides Corporate Update

FARMINGTON HILLS, Mich., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced that Ronil Patel, MS, SVP of Operations and Business Development and Charlie Hoffmann, MBA, SVP of Corporate Development, will participate in a Fireside Chat at the Canaccord 43rd Annual Growth Conference being held August 7-10, 2023 in Boston, MA and will present a company overview and participate in a panel at the H.C. Wainwright Ophthalmology Conference being held virtually on August 16, 2023.

Ocuphire Pharma to Present at the Canaccord 43rd Annual Growth Conference and the H.C. Wainwright Ophthalmology Conference in August

ASRS presentations will feature data from ZETA-1 Phase 2 trial evaluating APX3330 in diabetic retinopathy End-of-Phase 2 meeting with FDA for APX3330 scheduled for Q4 2023 FARMINGTON HILLS, Mich., July 26, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced that results from the ZETA-1 Phase 2 trial evaluating APX3330 in diabetic retinopathy will be presented at the American Society of Retinal Specialists (ASRS) annual scientific meeting to take place in Seattle, Washington, July 28 to August 1.

Ocuphire to Present at American Society of Retina Specialists Annual Meeting and OIS Retina Innovation Summit

Baytex Energy Corp

Taitron Components

Penny stocks have a horrible reputation for the most part and it's not necessarily undeserved. Too many times, charlatans hawk their junk securities, often in the over-the-counter market where regulations are far less stringent than in actual exchanges.

Surprise! These 3 Penny Stocks Pack Powerful Financials.

FARMINGTON HILLS, Mich., July 10, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), today announced that the Compensation Committee of its Board of Directors, which is composed entirely of independent directors, approved an equity award under Ocuphire's 2021 Inducement Plan, as a material inducement to a new hire in connection with such new hire's employment with the Company effective on July 10, 2023. The equity award was approved in accordance with Nasdaq Listing Rule 5635(c)(4), which also requires a public announcement of equity awards that are not made under a stockholder approved equity plan.

Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

FARMINGTON HILLS, Mich., June 27, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced that a late-breaking poster and ePoster theater presentation titled Oral APX3330 Reduces the DRSS Worsening after 24-weeks of Daily Treatment—Efficacy and Safety Results of the ZETA-1 Phase 2 Trial in Diabetic Retinopathy was presented by retina specialist and ZETA-1 clinical trial investigator, Victor H. Gonzalez, M.D. at the 83 rd Scientific Sessions of the American Diabetes Association (ADA) in San Diego, CA on Saturday, June 24, 2023.

Ocuphire Presents APX3330 ZETA-1 Clinical Data in Late-Breaker Session at the American Diabetes Association's Annual Conference

FARMINGTON HILLS, Mich., June 21, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of retinal and refractive eye disorders, today announced that Victor H. Gonzalez, MD will present a late breaking poster and ePoster theater presentation titled Oral APX3330 Reduces the DRSS Worsening after 24-weeks of Daily Treatment—Efficacy and Safety Results of the ZETA-1 Phase 2 Trial in Diabetic Retinopathy at the 83rd Scientific Sessions of the American Diabetes Association (ADA), in San Diego, CA, June 23-26.

Ocuphire Announces Late Breaking Presentation on APX3330 ZETA-1 Clinical Data at American Diabetes Association Annual Conference

FARMINGTON HILLS, Mich., June 12, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of retinal and refractive eye disorders, today announced that a presentation titled, Safety and Efficacy of an Oral Therapeutic APX3330 from ZETA-1 Phase 2 Trial in Patients with Diabetic Retinopathy, was delivered by David Lally, M.D. F.A.S.R.S. at the Clinical Trials at the Summit (CTS) 2023 meeting in Park City, Utah on Saturday, June 10. Dr. Lally is a member of Ocuphire's Medical Advisory Board. APX3330 was evaluated in patients with mild to moderate non-proliferative diabetic retinopathy (NPDR) and mild proliferative diabetic retinopathy (PDR).

News for Ocuphire Pharma Stock (OCUP)